We investigated the effects of a strong CYP3A4 inhibitor (itraconazole) or inducer (rifampicin) on the pharmacokinetics of the epidermal growth factor receptor-tyrosine kinase inhibitor osimertinib, in patients with advanced non-small cell lung cancer in two Phase I, open-label, two-part clinical studies. Part one of both studies is reported.
Introduction
Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) provide significant clinical benefit in patients with EGFR mutation-positive non-small cell lung cancer (NSCLC) [1] [2] [3] [4] [5] [6] [7] [8] ; however, many patients who initially respond to EGFR-TKIs develop acquired resistance [9] [10] [11] . Over 50% of such patients harbour the EGFR T790M resistance mutation [12] [13] [14] [15] [16] [17] [18] .
Osimertinib is a potent, oral, central nervous systemactive, irreversible EGFR-TKI, selective for both EGFR-TKI sensitizing (EGFRm) and T790M resistance mutations [19] [20] [21] [22] , and is recommended for the treatment of patients with T790M mutation-positive advanced NSCLC following disease progression on or after EGFR-TKI therapy [23, 24] .
In vitro data show that the metabolism of osimertinib and its active metabolites, AZ5104 and AZ7550, is primarily mediated by cytochrome P450 3A (CYP3A)4/5 [25] . Therefore, exposure of osimertinib and its metabolites may be affected by co-administered compounds that modify CYP3A4/5 in a clinical setting.
We report results from two Phase I clinical drug-drug interaction (DDI) studies, investigating the effect of a strong CYP3A4 inhibitor, itraconazole (NCT02157883), and a strong CYP3A inducer, rifampicin (NCT02197247), on the pharmacokinetics (PK) of osimertinib in patients with EGFRm NSCLC following progression on previous EGFR-TKI therapy.
Methods

Overall trial design
The itraconazole and rifampicin studies were Phase I, openlabel, single-arm, two-part studies in adult patients with EGFRm NSCLC who had progressed on an EGFR-TKI therapy. Key inclusion and exclusion criteria are shown in the Supporting Information, Key inclusion criteria and Key exclusion criteria. The studies were conducted in patients who were likely to benefit from treatment with osimertinib. Part A of each study is reported here; Part B investigated the safety and tolerability of osimertinib in these patients for approximately an additional 12 months. Patients were permitted to continue osimertinib beyond 12 months, on continued access, if there was evidence of clinical benefit.
Both studies were conducted in accordance with International Conference on Harmonization-Good Clinical Practice guidance; protocols were reviewed and approved by an Institutional Ethics Committee and Institutional Review Board. Informed consent was obtained from all patients. The commercial formulation of osimertinib 80 mg filmcoated tablet was used.
Study design
The primary objective was to investigate the effect of a strong CYP3A4 inhibitor, itraconazole, or strong CYP3A inducer, rifampicin, on the exposure of osimertinib. The secondary objective was to characterize the PK of osimertinib and its metabolites (AZ5104 and AZ7550) following oral dosing in the presence and absence of itraconazole or rifampicin. Evaluation of the safety and tolerability of osimertinib was a safety objective. The assessment of 4β-hydroxy-cholesterol (4βHC) as a marker of CYP3A4 induction potential was an exploratory objective in the rifampicin study.
Study designs are shown in Figure 1 (full details in Supporting Information, Itraconazole study design, Rifampicin study design). Itraconazole 200 mg twice a day was chosen to provide sufficient inhibition of CYP3A to demonstrate any drug interaction effects [26] [27] [28] . Due to the long terminal half-life (t ½λz ) of osimertinib and its metabolites, quantifiable pre-dose concentrations of osimertinib were expected in Period 2 (see Supporting Information, Itraconazole interaction study statistical analsyses, for carryover criteria) and, hence, three different approaches were applied for analysis. The primary analysis excluded Period 2 data for patients meeting carryover criteria for the affected analytes. A supplemental analysis included data for patients meeting carryover criteria evaluated as such, and an exploratory analysis, using carryover adjusted PK parameters, whereby the concentrations from Period 1 contributing to Period 2 were subtracted from Period 2 concentrations, was also performed. Rifampicin 600 mg once daily was selected as this dose has been shown to achieve maximum induction of CYP3A activity [29] . Rifampicin was administered for 21 days to allow full induction and attainment of any adjusted steady-state conditions.
Sample size
For osimertinib, a within-patient coefficient of variation (CV) of 34% was assumed for C max and area under the plasma concentration-time curve (AUC). It was planned to recruit 38 patients in both studies to achieve 30 evaluable patients. Assuming a 50% increase in osimertinib exposure with itraconazole, or a 33% decrease with rifampicin, the studies would have 90% power to detect the predefined bounds of the 90% confidence interval (CI) of the geometric mean ratio (GMR). Boundaries were based on data indicating that a less than twofold change in osimertinib exposure neither alters the risk-benefit of osimertinib nor requires dose adjustments [29] .
Analytical methods
Plasma samples were analysed by Covance Laboratories using validated bioanalytical methods. No analytically significant interferences from endogenous matrix components were observed at the retention times of each analyte in the matrix samples screened. All methods demonstrated acceptable selectivity with mean, normalized matrix factors of 1.00 ± 0.08 observed at the concentrations tested. The limit of quantification in the itraconazole study was 0.05 nM for osimertinib, 0.0515 nM for its metabolites, and 2.0 ng ml À1 for itraconazole and hydroxy-itraconazole. In the rifampicin study, the limit was 16 nM for osimertinib, 1.65 nM for its metabolites and 50 ng ml À1 for rifampicin. The accuracy ranged from 95% to 111% and precision ranged from 3.3% to 12.0% for all analytes in both studies. Further details are included in the Supporting Information, Analytical methods.
Statistical methods
The safety analysis set included all patients who received at least one dose of osimertinib. Safety was assessed by adverse event (AE) reporting, physical examination, vital signs, weight, standard 12-lead electrocardiogram (ECG), laboratory parameters and ophthalmologic examination (including Figure 1 Study design. EGFR, epidermal growth factor receptor; EGFRm, epidermal growth factor receptor-tyrosine kinase inhibitor sensitizing; NCSLC, non-small cell lung cancer; TKI, tyrosine kinase inhibitor slit lamp examination, blurred vision, and visual exam with additional tests as clinically indicated). AEs were classified according to the terminology of the Medical Dictionary for Regulatory Activities version 17.0 (itraconazole study) and 18.0 (rifampicin study), and graded for severity by Common Terminology Criteria for AEs (CTCAE) v4.0. All AEs are reported as preferred term. The PK analysis set included all patients who received at least one dose of osimertinib, had no important protocol deviations or events affecting PK, and were evaluable for at least one treatment period. Osimertinib exposure in the itraconazole study was assessed by AUC from zero extrapolated to infinity and maximum plasma concentration (C max ). Steady-state exposure of osimertinib in the rifampicin study was assessed by C max after multiple dosing (C ss,max ) and AUC from zero to the end of dosing (AUCτ). A no-effect limit on the PK of osimertinib after co-administration with itraconazole was predefined if the upper bounds of the 90% CIs for the geometric mean least square mean (GMLSM) ratios of osimertinib AUC and C max were both below 200%. A no-effect limit following co-administration with rifampicin was predefined if the lower bounds of the 90% CIs for the GMLSM ratios (Period 2 vs. Period 1) of osimertinib AUC and C ss,max were both above 50%. Confidence intervals of 90% were calculated for these analyses, based on FDA guidelines [30] .
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY [31] , and are permanently archived in the Concise Guide to PHARMA-COLOGY 2017/18 [32, 33] , or the PubChem database https://www.ncbi.nlm.nih.gov/pccompound.
Results
Patients
Of 47 patients enrolled in the itraconazole study, 39 were assigned to treatment (eight met an exclusion criterion) and 38 completed treatment in Part A. Of the 51 patients enrolled in the rifampicin study, 41 were assigned to treatment and 32 completed Part A of the study. Baseline patient demographics and disease characteristics are summarized in Table 1 . Fiftysix percent (22/39) and 98% (40/41) of patients received allowed concomitant medications in the itraconazole and rifampicin studies, respectively. Most common concomitant medications received during the itraconazole and rifampicin studies are shown in Table S1 .
Itraconazole study pharmacokinetics
The PK analysis set included 36 patients (three were excluded due to multiple osimertinib doses or had taken prohibited concomitant medication). As expected, quantifiable pre-dose concentrations of osimertinib metabolites were observed in Period 2. The majority of patients met the carryover criterion for AZ5104 and all patients met the carryover criterion for AZ7550; the numbers of patients with evaluable Period 2 data were: osimertinib, n = 31; AZ5104, n = 16; AZ7550, n = 0.
Osimertinib concentration-time profiles for osimertinib alone versus osimertinib plus itraconazole treatment are shown in Figure 2A and Table 2 . In the primary analysis, coadministration of osimertinib with itraconazole decreased osimertinib C max by approximately 20% and increased AUC by approximately 24% compared with osimertinib alone. The upper bound of the 90% CI of the GMLSM ratios (itraconazole + osimertinib/osimertinib alone) for AUC and C max (Table 2) were below the no-effect limit of 200%. Osimertinib in combination with itraconazole increased osimertinib median t max by approximately 2 h compared with osimertinib alone (P = 0.0002) ( Table 2 ). Analyses including the carryover concentrations (supplemental analysis) or data adjusted for carryover in Period 2 (exploratory analysis) were consistent with those from the primary analysis (Tables S2 and S3). Similarly, analyses only including patients evaluable at both Periods 1 and 2 were consistent with the overall PK analysis set (Table S4) .
Co-administration of osimertinib with itraconazole decreased AZ5104 C max by around 24% and increased AUC by approximately 8% compared with osimertinib alone (Table 2 ) without a relevant effect on metabolite:parent ratio (<10% of osimertinib in both treatment periods). Median AZ5104 t max was increased by around 19 h (P = 0.0181) ( Table 2 ). Similar trends were observed when data from patients meeting the carryover criterion were included (Table  S2) . When Period 2 data were adjusted for carryover from Period 1 (exploratory analysis), both C max and AUC decreased (by approximately 32% and 6%, respectively) (Table S3) .
Since all patients had AZ7550 carryover in Period 2 predose samples, the primary PK analysis did not include evaluable AZ7550 data for the osimertinib + itraconazole treatment, and results are solely based on the supplemental analysis (inclusion of patients with carryover in Period 2 ≥ 20% of C max ) and exploratory analysis (using carryover adjusted concentrations for Period 2). Co-administration of osimertinib with itraconazole decreased AZ7550 C max and AUC by approximately 56% and 51%, respectively, compared with osimertinib alone, and mean metabolite:parent ratios for C max and AUC decreased by approximately 50% (from <6% to <3% of osimertinib exposure; Table S2 ). There was no significant effect on t max . In the exploratory analysis, AZ7550 C max and AUC decreased by approximately 74% and 66%, respectively (Table S3 ). Across the two treatment periods, AZ7550 exposure amounted to <6% of exposure to osimertinib.
On Day 10, geometric mean itraconazole and hydroxyitraconazole C max values were 694 ng ml À1 and 1358 ng ml À1 , respectively. Geometric mean AUCτ values were 5298 ng h À1 ml À1 and 13 600 ng h À1 ml À1 , respectively. Geometric mean concentrations of both itraconazole and hydroxy-itraconazole were maintained above 100 ng ml
À1
over the entire dosing interval.
Rifampicin study pharmacokinetics
The PK analysis set included 41 patients, of whom 40 contributed data for osimertinib and its metabolites (one patient was excluded due to dosing deviation), and 39 patients for both 
Former 12 (31) 13 (32) ECOG PS, n (%) 0 6 (15) 10 (24) 1
(85) 31 (76)
Overall disease classification 
Prior platinum-chemotherapy, n (%) 24 (62) 25 (61) BMI, body mass index; ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; PS, performance status; TKI, tyrosine kinase inhibitor. a Metastatic disease (patient had any metastatic site of disease). b Locally advanced (patient had only locally advanced sites of disease).
rifampicin and 4β-hydroxy-cholesterol. Two and five patients discontinued treatment in Periods 2 and 3, respectively, due to worsening of their condition under investigation. A further two patients discontinued rifampicin due to AEs considered possibly causally related to study treatment by the investigators (grade 2 vomiting, n = 1; grade 3 neutrophil count decrease, n = 1) but entered Part B. Due to dosing deviations, non-compliance, prohibited medication or withdrawal, 38 patients had evaluable data in Period 1 (osimertinib alone), 32 patients in Period 2 (osimertinib + rifampicin) and 28 patients in Period 3 (osimertinib alone). Osimertinib concentration-time profiles for the three treatment periods are shown in Figure 2B and osimertinib, AZ5104 and AZ7550 PK parameters are summarized in Table 3 .
Rifampicin co-administration decreased osimertinib C ss,max and AUCτ by approximately 73% and 78%, respectively, compared with osimertinib alone at steady state (ss) prior to rifampicin administration. The upper bound of the 90% CI of the GMLSM ratios (rifampicin + osimertinib/osimertinib alone) for C ss,max and AUCτ (Table 4) were below the no-effect limit of 50%. Four weeks after rifampicin discontinuation, osimertinib C ss,max and AUCτ had returned to levels similar to those observed prior to rifampicin co-administration. Rifampicin had no significant effect on osimertinib t ss,max .
Similar decreases in C ss,max and AUCτ were observed for AZ5104 (Table 4) . Geometric mean metabolite:parent ratios for AZ5104 C ss,max and AUCτ ranged from around 8% to 11% across the three treatment periods and did not significantly change when osimertinib was administered alone in AZ7550 C ss,max and AUCτ increased during rifampicin co-administration (Table 4) , reflected by pronounced increases in metabolite to parent C ss,max and AUCτ ratios for AZ7550 (52% and 67%) compared with those observed with osimertinib alone (10% and 12%). Four weeks after discontinuation of rifampicin, AZ7550 C ss,max , AUCτ and metabolite: parent exposure ratios returned to levels observed prior to rifampicin treatment (Table 4) .
The effect of rifampicin co-administration on osimertinib, AZ5104 and AZ7550 plasma trough concentrations was evident 7 days after commencement of rifampicin administration, reaching ss by 3 weeks. Three weeks after rifampicin discontinuation, CYP3A4 induction appeared to have abated, as trough osimertinib (Figure 2C ), AZ5104 and AZ7550 plasma concentrations returned to levels observed prior to rifampicin administration.
Geometric mean (%GCV) C ss,max and AUCτ for rifampicin on Day 49 were 13810 ng ml À1 (40.6%) and 58 610 ng h À1 ml À1 (36.8%), respectively, indicating sufficient exposure and consistency with other studies where significant DDI has been demonstrated [34] . An approximate 10% increase in 4βHC levels relative to pre-dose baseline was c Median difference and confidence intervals calculated using the Hodges-Lehmann median estimator. d P-value for treatment difference in median t max calculated using the Wilcoxon signed rank test. e n = 33 f n = 30 g n = 31 h n = 15 i n = 28 Table 3 Summary of osimertinib, AZ5104 and AZ7550 PK parameters with and without rifampicin (PK analysis set) 
Safety
Itraconazole study. Osimertinib was well tolerated when administered alone or in combination with itraconazole (Table S5 ). All AEs were mild or moderate in intensity; with no grade ≥3 events and no AEs leading to treatment discontinuation or death. Across both treatment periods, 26 (67%) patients reported AEs. The most common all-causality AEs were nausea (n = 7, 18%) and vomiting (n = 6, 15%). Eight patients (21%) experienced AEs that the investigator considered possibly related to treatment. Of these, six patients experienced AEs that were considered possibly related to osimertinib and four to itraconazole. Nausea (n = 3) was the most common possibly treatment-related AE. Three patients experienced a serious AE (SAE), including lobar pneumonia (n = 1, possibly osimertinib-related), respiratory syncytial virus infection (n = 1) and hepatic enzyme increase (n = 1). There were no clinically significant changes in vital signs, ECG parameters, physical examinations, ophthalmic examinations or laboratory parameters.
Rifampicin study. Osimertinib administered alone or concomitantly with rifampicin was well tolerated (Table S5 ). The majority of AEs were mild or moderate in intensity, there were no AEs leading to death or discontinuation of osimertinib (two patients discontinued rifampicin due to AEs). Overall, 39 patients (95%) reported at least one AE (all causalities). The most frequently reported were diarrhoea (n = 13, 32%), dry skin (n = 10, 24%), fatigue and nausea (n = 8 each, 20%). Thirty-four patients (83%) had AEs considered by the investigator to be possibly causally related to study treatment; of these, 33 patients (80%) reported AEs that were possibly osimertinib-related and 15 (37%) had possibly rifampicin-related AEs. Of the AEs possibly causally related to osimertinib, (including both osimertinib and rifampicin), the most common were diarrhoea (nine patients [22%]), dry skin (nine patients [22%]), fatigue (six patients [15%]) and stomatitis (six patients [15%]). Ten patients had grade ≥3 AEs; of these, three patients had at least one AE that the investigator considered to be possibly causally related to study treatment. Seven patients experienced SAEs including hyperkalaemia (n = 1), malaise (n = 1), femur fracture (n = 1), thrombophlebitis (n = 1), influenza (n = 1), muscular weakness (n = 1) and cardiac failure congestive (n = 1, considered possibly related to osimertinib). There were no clinically significant changes in laboratory parameters, vital signs, ECGs or physical examination.
Discussion
Based on in vitro studies, co-administration of osimertinib with a potent CYP3A inhibitor or inducer, such as itraconazole or rifampicin, may have the potential to affect the exposure of osimertinib, AZ5104 and AZ7550. Hence, these studies were conducted to understand the overall impact and clinical relevance of inhibiting or inducing CYP3A4 on the PK of osimertinib and its metabolites in a clinical setting.
In vitro data indicate that osimertinib is a P-gp and BCRP substrate with saturation of efflux evident at higher concentrations, and that efflux can be inhibited with a P-gp or BCRP inhibitor [20] . At the clinical dose of 80 mg (inlet concentration of 640 μM), osimertinib is unlikely to be a victim of P-gp or BCRP inhibitors or inducers. The maximum influx rate was 1.13 and 1.11 for OATP1B1 and OATP1B3 [20] , indicating osimertinib is not a substrate of these transporters.
There was a slightly higher proportion of white patients in the rifampicin study compared with the itraconazole study; however, this is unlikely to affect our results since it has previously been shown that osimertinib exposure is not affected by ethnicity [29] .
For the itraconazole study, a fixed-sequence crossover design in which the potential substrate, or 'victim' drug (osimertinib), is administered alone and then again in combination with a potential 'perpetrator' (itraconazole) was selected. A randomized crossover design was considered inappropriate for this NSCLC population, as substantial washout periods, where patients would be without treatment, would be required. Similarly, a parallel design was not appropriate because of the heterogeneous population across multiple sites and countries. A single dose, rather than steady-state study was chosen because osimertinib demonstrates time-independent and linear PK.
PK sampling duration was limited to 216 h between osimertinib doses due to medical and ethical considerations. Hence, pretreatment with itraconazole dosing started on Day 6, while osimertinib and metabolite samples were still collected during Period 1. It was anticipated that the primary endpoints, specifically osimertinib AUC and C max , would be suitably characterized in Period 1 over a 120-h dosing period prior to initiation of itraconazole on Day 6. However, AUC could not be reliably determined in all patients using sampling points over the initial 120-h (itraconazole-free) period (<80% of the AUC was characterized in >20% of patients). The carryover limitation was addressed in the supplementary and exploratory analyses for all analytes, the results of which did not change the overall conclusions of the study. Start of itraconazole dosing while collecting the terminal PK samples in Period 1 on Days 8 and 10 was not expected to meaningfully affect the results obtained for osimertinib as, on average, greater than 75% of AUC was characterized over the first 120 h. Even if there was a significant effect of itraconazole on the terminal phase of osimertinib between Days 6 and 10 of Period 1, the effect on osimertinib AUC 0-inf would not be sufficient to alter the conclusions from the study.
In this study, an itraconazole dose of 200 mg twice daily was administered for 9 days. Osimertinib was co-administered on the fifth day of itraconazole administration and itraconazole dosing continued for an additional 4 days to maintain full CYP3A4 inhibition. Previous studies have reported that 4-5 days of itraconazole 200 mg once daily are sufficient to result in drug interaction effects on CYP3A substrates [26] [27] [28] 35] . The mean plasma concentrations of itraconazole and hydroxy-itraconazole were greater than 100 ng ml À1 during the entire dosing interval, which has been shown to be sufficient to inhibit CYP3A4 [36] .
Co-administration of osimertinib with itraconazole had no clinically relevant effect on osimertinib C max (80%; 90% CI 73, 87) and AUC (124%; 95% CI 115, 135), based on the pre-specified upper bound limit of 200% for the 90% CIs of the GMLSM treatment ratios. The decrease in C max and increase in AUC were due to the inhibition of CYP3A by itraconazole affecting the elimination of osimertinib and its metabolites. Itraconazole in combination with osimertinib increased osimertinib median t max by approximately 2 h compared with osimertinib alone (P = 0.0002), indicating that co-administration with itraconazole impacts osimertinib absorption. The changes in exposure parameters of the active metabolite AZ5104 were also considered not clinically relevant. When osimertinib data were analysed, including the carryover concentrations (supplemental analysis), or data adjusted for carryover in Period 2 (exploratory analysis), similar effects on the treatment ratios of osimertinib and AZ5104 AUC and C max were observed.
Administration of rifampicin in combination with osimertinib decreased osimertinib C ss,max and AUCτ compared with administration of osimertinib alone at steady-state prior to rifampicin administration. The observed exposure of rifampicin was similar to that reported in the literature, which is sufficient to induce significant CYP3A4 enzyme activity [36, 37] . Four weeks after rifampicin discontinuation, osimertinib C ss,max and AUCτ had returned to similar levels to those observed prior to rifampicin co-administration. A similar change in exposure was observed for AZ5104 across the treatment periods, while AZ7550 exposure increased during rifampicin coadministration. This increase in AZ7550 exposure was small (30% for AUCτ and 40% for C max ) and not considered clinically significant. The reason for the increase in AZ7550 when dosed with rifampicin in contrast with AZ5104 could be due to the formation rate of AZ7550 being considerably greater than the elimination rate, which might not be the case for AZ5104. The exposure of rifampicin in this study is consistent with other studies where significant DDI have been demonstrated [34] .
In vitro studies indicated that other CYPs (CYP1A2, 2A6, 2C9 and 2E1) play a minor role in metabolism of osimertinib, along with direct conjugation with glutathione or other plasma proteins [25] . Moreover, in the human absorption, distribution, metabolism and excretion (ADME) study, approximately 30% of the osimertinib dose was excreted in faeces as bound to proteins, which was considered likely to be one of the eliminatory pathways [25] . A disconnect between in vivo and in vitro clearance attributed to extrahepatic (covalent) conjugation to glutathione is not captured adequately in the hepatocyte system [38] . This suggests that preclinical hepatocyte and recombinant CYP studies may overestimate the contribution of cytochrome P450 metabolism to the clearance of osimertinib in the clinic [25] . Availability of multiple elimination pathways could explain the lack of significant effect of itraconazole co-administration. Rifampicin is a pleiotropic inducer of multiple pregnane X receptorinducible drug-metabolizing enzymes and transporters of several CYPs including CYP3A [39] . This pleiotropic effect may be contributing to the overall osimertinib metabolism and decreasing exposure. A similar effect has been observed for other agents (tivozanib, ixazomib) where there is no effect with CYP3A inhibitor co-administration, but a clinically meaningful effect when co-administered with rifampicin, which is suggestive of induction of upstream nuclear hormone receptor pathways and multiple enzymes [40] [41] [42] .
Co-administration of osimertinib with itraconazole increased AZ5104 AUCτ by approximately 8%, and coadministration with rifampicin decreased AZ5104 AUCτ by approximately 81%. Modulation of CYP3A activities affected AZ5104 and osimertinib exposure to a similar extent, suggesting a greater effect on clearance of AZ5104 than on formation from osimertinib.
Co-administration of osimertinib with itraconazole decreased AZ7750 AUCτ by approximately 51%. Co-administration with rifampicin increased AZ7750 AUCτ by approximately 30%. These results suggested that modulation of CYP activities were affected by the formation rate of AZ7550 more than its clearance. However, as the exposures of the AZ5104 and AZ7550 (in terms of C ss,max and AUCτ) were still much lower than that of osimertinib following co-administration with a strong CYP3A inhibitor or inducer, their contributions to the overall safety and efficacy profile during induction or inhibition are likely to be small relative to osimertinib.
Concentrations of 4βHC increased by approximately 10% relative to baseline after osimertinib administration for 4 weeks, a relatively small change compared with an approximately sevenfold increase following 3 weeks of rifampicin administration. This increase was higher than that typically seen in shorter (10-14 day) induction studies with rifampicin and is likely due to the long (approximately 17 day) half-life of 4βHC [43] [44] [45] . Three weeks after discontinuation of rifampicin, 4βHC concentrations decreased but remained approximately twofold higher than baseline, consistent with the long half-life of 4βHC. This indicates that the CYP3A induction potential of osimertinib is low.
Lung cancer patients may have co-morbidities, necessitating the use of agents including CYP3A4 inhibitors. Here we demonstrate that osimertinib, at approved doses, can be co-administered with CYP3A4 inhibitors. Strong CYP3A inducers are not likely to be co-administered with osimertinib. However, it was noted by study investigators during the rifampicin study that patients who were deriving benefit during the initial treatment with osimertinib alone (until Day 28) had their disease-related symptoms return during rifampicin co-administration, leading to significant disease-related adverse events in Period 2. The patients improved significantly and again derived benefit from osimertinib during Period 3 when rifampicin was discontinued and osimertinib was administered alone. Our results indicate that in oncology-DDI studies, the effect of treatments on disease improvement and/or progression must be considered during study design, and on analysis of results. Efficacy was not a study objective but these patient-related observations provide evidence that co-administration of strong CYP3A4 inducers with osimertinib should be avoided, if possible. Physiologically based PK analysis has led to a recommendation for dose adjustment to 160 mg if the co-administration of strong inducers is unavoidable [46] .
Osimertinib 80 mg, administered with or without CYP3A inhibitors/inducers, was well tolerated in both studies with no new safety signals. Our results indicate that CYP3A4 inhibitors have no clinically significant effect on osimertinib exposure; however, co-administration of osimertinib with strong CYP3A inducers decreases osimertinib exposure and hence should be avoided where possible. These clinical study results are reflected in the prescribing information for osimertinib [46] . 
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